A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Gbm
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) No known IDH mutation. 2) Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment. 3) Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review. 4) Adequate hematologic, renal, and hepatic function.

You may not be eligible for this study if the following are true:

  • 1) Prior therapy for tumor except for resection. 2) Current or planned treatment with any other investigational agents for the study cancer. 3) Definitive clinical or radiologic evidence of metastatic disease outside the brain.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.